Literature DB >> 27758825

Absence of CALR mutations in JAK2-negative polycythemia.

Aurélie Chauveau1, Olivier Nibourel2, Sylvie Tondeur3, Damien Luque Paz4, Olivier Mansier5, Franciane Paul6, Mathieu Wemeau7, Claude Preudhomme2, Eric Lippert1, Valérie Ugo8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27758825      PMCID： PMC5210252          DOI： 10.3324/haematol.2016.154799

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.

Authors:  T Balligand; Y Achouri; C Pecquet; I Chachoua; H Nivarthi; C Marty; W Vainchenker; I Plo; R Kralovics; S N Constantinescu
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

2.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

3.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

4.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Authors:  Ilyas Chachoua; Christian Pecquet; Mira El-Khoury; Harini Nivarthi; Roxana-Irina Albu; Caroline Marty; Vitalina Gryshkova; Jean-Philippe Defour; Gaëlle Vertenoeil; Anna Ngo; Ann Koay; Hana Raslova; Pierre J Courtoy; Meng Ling Choong; Isabelle Plo; William Vainchenker; Robert Kralovics; Stefan N Constantinescu
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

8.  Presence of calreticulin mutations in JAK2-negative polycythemia vera.

Authors:  Julien Broséus; Ji-Hye Park; Serge Carillo; Sylvie Hermouet; François Girodon
Journal:  Blood       Date:  2014-10-10       Impact factor: 22.113

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  Thrombopoietin receptor is required for the oncogenic function of CALR mutants.

Authors:  H Nivarthi; D Chen; C Cleary; B Kubesova; R Jäger; E Bogner; C Marty; C Pecquet; W Vainchenker; S N Constantinescu; R Kralovics
Journal:  Leukemia       Date:  2016-02-17       Impact factor: 11.528
View more
  2 in total

Review 1.  Genetic Background of Polycythemia Vera.

Authors:  Mathilde Regimbeau; Romain Mary; François Hermetet; François Girodon
Journal:  Genes (Basel)       Date:  2022-04-02       Impact factor: 4.141

Review 2.  JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.

Authors:  Naseema Gangat; Natasha Szuber; Animesh Pardanani; Ayalew Tefferi
Journal:  Leukemia       Date:  2021-05-21       Impact factor: 11.528
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.